Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic tuftsin-derived neuroactive heptapeptide
Selank is a seven-amino-acid tuftsin-derived peptide researched mainly for anxiety, stress, cognition, and immune signaling. Small human studies report anxiety-related signals, but there is no modern large placebo-controlled program establishing efficacy or long-term safety.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Selank is a seven-amino-acid peptide derived from tuftsin, a naturally occurring immune-related fragment. It has been researched mainly for anxiety, stress, cognition, and immune signaling.
Small human studies reported anxiety-related signals, while animal and laboratory work explored brain and immune pathways. Researchers want to know whether those early findings become reliable clinical benefit.
A 62-person randomized study found anxiety improvement similar to an older comparison drug, but it had no placebo group and limited masking detail. Other small comparison or add-on studies reported related signals. An imaging study showed acute connectivity changes without demonstrating better symptoms or function.
Modern placebo-controlled replication, clinically meaningful effect size, pharmacokinetics, product-form differences, interactions, dependence or withdrawal, immunogenicity, uncommon harms, and long-term repeated-use safety remain uncertain. Early regional studies do not establish broad cognitive or wellness effects.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A randomized study investigated intranasal Selank in adults with generalized anxiety disorder or neurasthenia, comparing it with the active drug medazepam.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Older anxiety comparator and add-on studies, acute imaging, and biomarker research exist, but no large modern placebo-controlled program was located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The human studies are short, small, incompletely masked, and not independently replicated, while mechanism claims remain mostly preclinical.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was small, short, used an active comparator without a placebo arm, and provides limited accessible masking detail. It has not been independently replicated in a modern pivotal program and cannot establish long-term safety or broad cognitive effects. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
A 62-person randomized active-comparator study reported anxiety improvement similar to medazepam, while a separate 60-person comparison and 70-person add-on study reported related signals. The studies were small, short, and not independently replicated in a modern placebo-controlled program.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether Selank provides reproducible clinical anxiety benefit and what formulation-specific pharmacokinetics, dose-response, interactions, dependence or withdrawal profile, immunogenicity, rare harms, and long-term repeated-use safety look like.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
One small report measured IL-6 and Th1/Th2-related biomarker changes in patients and blood cultures.
It extends the four-amino-acid tuftsin sequence with Pro-Gly-Pro and is also called TP-7.
Salt form and terminal chemical modifications can change identity, stability, impurities, and exposure.
A 62-person active-comparator study and a 60-person phenazepam comparison reported anxiolytic signals.
The human record is promising but too small and methodologically limited to support broad clinical certainty.
Older reports described fewer unwanted effects, but they were not designed or powered to establish dependence, withdrawal, rare harms, or long-term comparative safety.
The reported signal involved amygdala connectivity with temporal and parahippocampal regions.
Rat studies found partially GABA-like transcriptional changes, and related experiments examined specific GABA binding.
This is a preclinical neurotrophin signal often used to support memory or neuroprotection claims.
The modern traceable human record contains acute imaging and small anxiety studies rather than validated healthy-cognition outcomes.
Current FDA material addresses compounding risk and eligibility, not an approved Selank drug product or indication.
The concerns include aggregation, peptide-related impurities, and inadequate human safety information.
Historical studies generally used intranasal research products, while current commercial forms may differ in identity and quality.
The located human reports were small and did not provide a modern comprehensive safety program.
Mechanisms
Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro; TP-7) is a synthetic analogue derived from the tuftsin sequence. Human evidence includes small active-comparator anxiety studies, an add-on phenazepam report, a cytokine-biomarker study, and a 52-person acute resting-state fMRI experiment. GABA-related transcription, BDNF, stress behavior, and enkephalin-enzyme findings are primarily animal or laboratory evidence.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Acute placebo-comparison resting-state fMRI study
52 healthy adults assigned to Selank, Semax, or placebo groups
The study reported acute group and time differences involving right-amygdala connectivity with right temporal and parahippocampal regions.
Study administration: Acute Selank, Semax, or placebo exposure; exact group sizes and route details are not fully reported in the accessible abstract
Limitations: Imaging changes are surrogate findings and do not demonstrate less anxiety, improved focus, better memory, functional benefit, or durability. Group sizes and full allocation or masking methods are not clear from the abstract.
Randomized active-comparator study
62 adults with generalized anxiety disorder or neurasthenia; 30 received Selank and 32 received medazepam
Both groups improved on anxiety measures, and the authors reported similar anxiolytic effects with additional antiasthenic or psychostimulant findings for Selank.
Study administration: Intranasal Selank versus oral medazepam in the historical study; the study regimen is not current dosing guidance
Limitations: Small active-comparator study, no placebo arm, limited accessible randomization and masking detail, Russian-language publication, short follow-up, and no independent modern replication.
Controlled rat chronic-mild-stress and elevated-plus-maze experiment
Male Wistar rats
Selank and diazepam produced context-dependent behavioral effects, while the combination most fully reduced the stress-associated anxiety measure in this rat model.
Study administration: Selank, diazepam, the combination, or saline
Limitations: Rat stress behavior cannot establish human combination benefit, benzodiazepine dose reduction, interaction safety, or a clinical treatment strategy.
Rat frontal-cortex neurotransmission gene-expression study
Rats
Selank altered many neurotransmission-related transcripts, with partial overlap between Selank- and GABA-associated expression patterns.
Study administration: Selank or GABA administered to rats
Limitations: Gene-expression similarity is indirect evidence and does not prove direct GABA-A receptor binding, a human anxiolytic mechanism, clinical efficacy, or safety.
Small add-on comparative study
70 adults with anxiety-spectrum disorders
The authors reported greater or faster therapeutic effects and fewer phenazepam-related complaints when Selank was added.
Study administration: Phenazepam alone versus phenazepam with intranasal Selank
Limitations: Add-on design cannot isolate Selank monotherapy, placebo and masking details are limited, adverse effects were not characterized like a modern safety trial, and the finding has not been independently replicated.
Comparative clinical study
60 adults with phobic-anxiety or somatoform disorders
The authors reported anxiety improvement, mild nootropic effects, and persistence of the anxiolytic effect for one week after Selank.
Study administration: Selank compared with phenazepam; historical administration details are not recommendations
Limitations: The accessible abstract does not establish placebo control, robust masking, allocation concealment, prespecified statistical methods, or independent replication. Subjective and clinical endpoints were reported in a small single-country study.
Human cytokine and ex vivo peripheral-blood study
Patients with generalized anxiety disorder, neurasthenia, or depression plus healthy controls in ex vivo comparisons
The report described Selank-associated changes in IL-6 and cytokine-balance measures.
Study administration: Selank exposure in patients and Selank incubation in peripheral-blood cultures
Limitations: Sample size and complete clinical methods are unclear from the accessible record, the endpoints are biomarkers, and the study does not establish infection prevention, immune enhancement, autoimmune treatment, or clinical outcome benefit.
Controlled rat hippocampal gene-expression experiment
Rats
Selank changed BDNF expression in the rat hippocampus after intranasal administration.
Study administration: Intranasal Selank or control in rats
Limitations: A molecular change in rat brain does not demonstrate human memory, focus, mood, neuroprotection, brain repair, or long-term safety.
Ex vivo human-serum enzyme assay
Human serum samples tested outside the body
Selank inhibited measured enkephalin-degrading activity in the serum assay.
Study administration: Selank added to human serum enzyme preparations
Limitations: An ex vivo biochemical effect is not a human exposure, receptor, pharmacokinetic, anxiety-outcome, cognition, or safety study.
Safety snapshot
Short- and long-term human safety, pharmacokinetics, interactions, immunogenicity, and repeated-use effects remain poorly characterized.
No direct evidenceLack of reported harm in small studies is not evidence of safety, and it cannot exclude rare or delayed events.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
FDA identifies compounded Selank acetate as presenting potential peptide-quality and immunogenicity concerns.
No direct evidenceThis is a product-quality and safety-information boundary; it does not quantify event incidence or prove that every product causes harm.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2026-05-14
2020-04-01
2020-01-01 · PMID 32342318 · DOI 10.1134/S001249662001007X
2017-01-01 · PMID 28280289 · DOI 10.1155/2017/5091027
2016-02-01 · PMID 26924987 · DOI 10.3389/fphar.2016.00031
2015-01-01 · PMID 26356395 · DOI 10.17116/jnevro20151156133-40
2014-01-01 · PMID 25176261
2008-01-01 · PMID 18454096
2008-01-01 · PMID 18577961
2008-01-01 · PMID 18841804
2001-01-01 · PMID 11550013